Compare Packaging Corporation of America (PKG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Packaging Corporation of America vs TG Therapeutics Inc — how do they compare? Packaging Corporation of America trades at $231.22 (market cap $20.49B), while TG Therapeutics Inc trades at $54.94 (market cap $8.16B). The key difference: Packaging Corporation of America is far larger — about 2.5× TG Therapeutics Inc's market cap, and Packaging Corporation of America pays a 2.61% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Packaging Corporation of America for 45 Days and TG Therapeutics Inc for 15 Days on average.
| PKG | TGTX | |
|---|---|---|
Market Cap | $20.49B | $8.16B |
Volume | 493,499 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $257.43 | $59.06 |
52-Week Low | $191.68 | $26.94 |
Typical Hold Time | 45 Days | 15 Days |
Enterprise Value | $24.30B | $8.37B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Packaging Corporation of America (PKG) trades at $227.25, down 1.08% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with Q2 2026 beating estimates but net income margin projected to decline in 2026. Analyst consensus is a Buy with a $272.43 price target, though technical indicators suggest near-term pressure with support at $225.
PKG offers a stable dividend and benefits from consistent packaging demand, but faces headwinds from cost pressures and negative cash flow. Investment appeal hinges on execution against margin challenges and the upcoming Q3 earnings report. Risks include rising input costs and competitive pressures in the industrial packaging sector.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% on the day, with a bearish technical signal from moving averages despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results have missed expectations. Analyst sentiment remains largely positive, with an 84.62% buy rating and a consensus price target of $80.50, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook for TGTX is mixed, with robust revenue guidance and product momentum offset by earnings misses and negative cash flow. Key opportunities include BRIUMVI's expanding market share and potential buyout speculation, but risks involve ongoing legal scrutiny, competitive pressures, and the need to translate top-line growth into consistent bottom-line performance amid significant cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
